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Lung cancer is the leading cause of cancer death worldwide and nearly 90% of cases
are attributable to smoking. Quitting smoking and early diagnosis of lung cancer, through
computed tomographic screening, are the only ways to reduce mortality from lung can-
cer. Recent epidemiological studies show that risk prediction for lung cancer is optimized
by using multivariate risk models that include age, smoking exposure, history of chronic
obstructive pulmonary disease (COPD), family history of lung cancer, and bodymass index.
It has also been shown that COPD predates lung cancer in 65–70% of cases, conferring
a four- to sixfold greater risk of lung cancer compared to smokers with normal lung func-
tion. Genome-wide association studies of smokers have identiﬁed a number of genetic
variants associated with COPD or lung cancer. In a case–control study, where smokers
with normal lungs were compared to smokers who had spirometry-deﬁned COPD or his-
tology conﬁrmed lung cancer, several of these variants were shown to overlap, conferring
the same susceptibility or protective effects on both COPD and lung cancer (independent
of COPD status). In this perspective article, we show how combining clinical data with
genetic variants can help identify heavy smokers at the greatest risk of lung cancer. Using
this approach, we found that gene-based risk testing helped engage smokers in risk miti-
gating activities like quitting smoking and undertaking lung cancer screening.We suggest
that such an approach could facilitate the targeted selection of smokers for cost-effective
life-saving interventions.
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EPIDEMIOLOGY OF COPD
Chronic obstructive pulmonary disease (COPD) is characterized
by ﬁxed airﬂow obstruction, measured by spirometry as a reduced
forced expiratory volume in 1 s (FEV1; Mannino et al., 2006).
Based on both cross-sectional and prospective studies, it is esti-
mated that 20–30% of smokers develop signiﬁcant COPD while
the remainder maintain near normal lung function (Løkke et al.,
2006; Mannino et al., 2006; Kohansal et al., 2009). When smokers
are stratiﬁed by smoking exposure dose, the distribution of %pre-
dicted FEV1 shifts from unimodal in light smokers to a trimodal
distribution in heavy smokers (Figure 1; Young et al., 2007). This
shift to trimodal distribution, following chronic smoke exposure,
deﬁnes susceptible smokers with COPD and healthy smokers who
are resistant to the effects of smoking. This observation shows that
after three to four decades of heavy smoking exposure, a differ-
ential response to smoking can be observed that is independent
of smoking exposure dose (Young et al., 2007). Such a discordant
response to smoking exposure is consistent with a “pharmaco-
genetic effect” where variation in genetic makeup determines a
person’s response to smoking exposure (i.e., drug exposure). These
observations argue strongly in favor of a signiﬁcant gene-by-
environment effect whereby COPD occurs in smokers who are
genetically susceptible and heavily exposed to decades of smoking
(Molﬁno, 2004; Young and Hopkins, 2011d). Such an observation
is unique in common complex diseases by deﬁning two distinct
phenotypes – susceptible (responder) phenotype (smokers with
COPD) and resistant (non-responder) phenotype (smokers with
normal lung function; Young et al., 2007).
Although 80–90% of those diagnosed with COPD have signiﬁ-
cant smoking exposure, there remains a groupof 10–20% that have
either been chronic asthmatics or people chronically exposed to
other aero-pollutants (occupational dusts, passive tobacco smoke,
or smoke from domestic cooking; Mannino et al., 2006). Irrespec-
tive of exposure, it is generally accepted thatCOPDresults from the
combined effects of a chronic airway inﬂammatory stimulus and
host genetic susceptibility (Molﬁno, 2004; Young and Hopkins,
2011d). Twin studies have suggested that genetic factors underlie
variation in airﬂow obstruction with an estimated heritability of
40–75% (Chen, 1999). This makes lung function a strong genetic
trait in comparison with many other diseases or physiological
states. While we conclude from these studies that reduced FEV1
(or reduced%predicted FEV1), characterizingCOPD, is under sig-
niﬁcant genetic inﬂuence, smoking is an environmental exposure
critical to the development of most COPD (and the penetrance
of relevant “COPD” genes). As the relationship between smoking
exposure and FEV1 may not be simply linear (Castaldi et al., 2011),
simple adjustment by regression analyses may not be appropriate
in case–control studies poorly matched for smoking history. We
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FIGURE 1 |Trimodal distribution of %predicted FEV1 in current and
former smokers with heavy smoke exposure defining “susceptible”
and “resistant” smokers (modified from Burrows et al., 1977).
believe that much of the failure to replicate genetic associations
in complex disease is due to small sample size and important dif-
ferences in study design – in particular variation in deﬁning the
disease and control phenotype and, failure to allow for the effect
of variable age and environmental exposure on expression of the
phenotype (i.e., penetrance; Silverman et al., 2011). We suggest
that COPD is an excellent example of a complex disease because
the susceptible and non-susceptible (resistant or non-responder)
phenotypes can be clearly deﬁned and the critical environmental
exposure of smoking can be measured allowing stratiﬁcation or
matching to be done.
EPIDEMIOLOGY OF LUNG CANCER
Like COPD, 85–90% of lung cancer can be attributed to smok-
ing exposure (Alberg and Samet, 2003). While smoking is almost
a pre-requisite to getting lung cancer, other risk factors are rele-
vant. Age is an important risk factor for lung cancer risk, with risk
increasing exponentially after age 60 years old in smokers com-
pared to non-smokers (Woloshin et al., 2008). When age and pack
year exposure are compared with reduced FEV1 in a multivari-
ate analysis, reduced FEV1 (COPD) confers a ﬁvefold increased
risk of lung cancer, two- to threefold greater than that con-
ferred by age or pack years alone (Burrows et al., 1977). Indeed
prospective studies have shown that COPD predates lung can-
cer in 65–70% of all cases (de Torres et al., 2007; Wilson et al.,
2008; Young et al., 2009b). If computed tomographic (CT)-based
emphysema is also assessed, then 85–90% of lung cancer cases
have either spirometry-deﬁned COPD and/or CT-based emphy-
sema (de Torres et al., 2007; Wilson et al., 2008). Other risk factors
for lung cancer include exposure to occupational dusts (asbestos,
coal, and silica), low body mass index (BMI) and low educa-
tional level (Tammemagi et al., 2011). While 10–15% of lung
cancer cases are “non-smokers,” with a predominance of women,
it is not yet clear what role other aero-pollutant exposures play
(e.g., passive smoke or cooking smoke). To date, there are too
few genetic studies in this group to make any ﬁrm conclusions
about contributing genes. Another area of uncertainty in lung
cancer genetics is the relevance of genes underlying mechanisms
deﬁning the histological subtypes of lung cancer. For this rea-
son, lung cancer refers to small cell and non-small cell subtypes
secondary to smoking and hereafter is described as a single dis-
ease for the purposes of this review although this is unlikely to be
the case.
In contrast to COPD, twin studies suggest heritability of lung
cancer is only 15–25% suggesting other factors such as smoking
history and susceptibility to COPD are of importance (Lichten-
stein et al., 2000). Detailed studies of family history however show
that having one ﬁrst degree relative with lung cancer increases
your risk by 1.5- to 2-fold that of someone with no family history
(Jonsson et al., 2004). While some advocate that family history is a
very good marker of “genetic risk” (Valdez et al., 2010), this com-
pletely overlooks the over-riding requirement of a smoking history
(reducing penetrance of lung cancer disposition in non-smokers)
and that a positive family history is reported in only 20% of cases
(low sensitivity; Young et al., 2009b). This contrasts with COPD
where a positive family history is found in 30–40% of those with
COPD (Young et al., 2011b).
With the recent interest in screening for lung cancer using com-
puted tomography of the lung (National Lung Screening Trial
Research Team, 2011), there has been growing interest in the role
of “COPD” in lung cancer risk (Sekine et al., 2012). Several lung
CT screening studies have reported their ﬁndings on the relative
importance of spirometry-deﬁned FEV1 and CT-deﬁned emphy-
sema in lung cancer (de Torres et al., 2007; Mohamed Hoesein
et al., 2011; Sekine et al., 2012). While molecular studies implicate
both these processes in the development of lung cancer (Young and
Hopkins, 2011b), there remains debate about the relative impor-
tance of emphysema and reduced FEV1 in susceptibility to lung
cancer. To date only one study has published results which showed
that spirometry-deﬁnedCOPDandCT-based emphysema overlap
in 70% of cases and are independently associated with increas-
ing risk of lung cancer (de Torres et al., 2007). We conclude that
susceptibility to “COPD” is the most important marker of a pre-
disposition to lung cancer in smokers beyond that of how much
you smoke (Young and Hopkins, 2011c).
OVERLAPPING GENETIC VARIANTS AND
MOLECULAR BIOLOGY
Over the last 4 years many studies have published the results of
genome-wide association (GWA) studies of COPD or lung cancer
(El Zein et al., 2012). Consistent with the epidemiological studies
of the last 40 years, none of the lung cancer GWA studies have
considered the possible role of COPD in the associations they
have reported (El Zein et al., 2012). Basically, given the close rela-
tionship between COPD and lung cancer, it is very possible that
some of the associations described in the lung cancer GWA stud-
ies are in fact due to associations with COPD (Young et al., 2008,
2010b, 2011c,d; Lambrechts et al., 2010; de Andrade et al., 2011).
This possibility arises because COPD is commonly undiagnosed,
unless spirometry is routinely done on all study subjects, and that
the frequency of COPD in the lung cancer case–control studies is
almost certainly at least twofold different between cases and con-
trols. This is because the prevalence of COPD in lung cancer case
series is consistently about 65–70% (de Torres et al., 2007; Wil-
son et al., 2008; Young et al., 2009b) and about 20% in unselected
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smoking “controls” (Hill et al., 2010). This means that any associ-
ation reported in a lung cancer case–control study, where COPD
has not been routinely measured (and stratiﬁed for), might have
spuriously attributed their ﬁnding to lung cancer when it might
actually be related to COPD (Young et al., 2008, 2011b).
We were the ﬁrst to show this “confounding” effect in 2008,
just months after the ﬁrst gene for lung cancer was reported
in the journals “Nature” and “Nature Genetics” (Young et al.,
2008). This observation was possible because we compared the
allele and genotype frequencies of the most important “lung
cancer” SNP in a study that involved three groups of smokers
comprising those with COPD, normal lung function (resistant
smokers) and lung cancer (sub-phenotyped for COPD by spirom-
etry). By comparing the frequency of the “lung cancer” causing
allele of the nicotinic receptor gene across these three groups,
we found the disease allele was increased in COPD and in
lung cancer with pre-existing COPD. The frequency of this dis-
ease allele was only slightly increased in those with lung cancer
alone (but not signiﬁcant). We have gone on to show something
very similar for three other GWA genes recently implicated in
COPD that are also relevant to lung cancer (Young et al., 2010b,
2011c,d). Interestingly, all of the overlapping genes implicated
by the GWA studies encode proteins known to be expressed by
lung epithelium and involved in various inﬂammatory pathways
(Young and Hopkins, 2011a).
While more studies are needed to conﬁrm these ﬁndings, they
suggest that themolecular pathways underlyingCOPDmay also be
related to lung cancer development. This has important implica-
tions in future studies of lung cancer, as it suggests that lung cancer
and COPD should be thought of as closely related diseases. To
illustrate this point about mistaken association, we have recently
published a study of the GSTM1 null genotype and found that it
is exclusively related to COPD and not lung cancer as previously
reported (Young et al., 2011b). This implies that past lung cancer
studies reporting genetic associations might have been mistaken,
an error that is relevant to most lung cancer studies published
to date. To summarize, there is strong evidence from the GWA
studies to suggest that genes underlying COPD and lung cancer
overlap and, that the pathways they implicate involve epithelial cell
signaling of several inﬂammatory pathways (Young and Hopkins,
2011b,c; Young et al., 2011a).
In addition to the ﬁndings described above, there has been
a growing interest in the cell signaling pathways involved in the
development of both COPD and lung cancer (Houghton et al.,
2008; Young et al., 2009a; Caramori et al., 2010; Yang et al., 2011).
To date, it appears that smoking incites an exaggerated or pro-
longed inﬂammatory state in the lung, conferred in part by genetic
effects and, dominated by neutrophils and macrophages derived
from the systemic circulation. These immune cells of the innate
system orchestrate a process of epithelial and mesenchymal tissue
remodeling where, to varying degrees, the epithelium produces
excessive mucus, the airways of the lungs become ﬁbrotic and the
alveoli (air sacs) are destroyed. While the exact mechanisms are
not yet understood, early evidence suggests these processes result
from a microclimate of excessive growth factors and matrix met-
alloproteinase activity. Such a microclimate has been implicated
in the development of many cancers including lung cancer (Young
and Hopkins, 2011b). It is possible that the exact pathways under-
lying COPD and lung cancer, or both, maybe further elucidated
by genetic epidemiological studies (El Zein et al., 2012).
RISK PREDICTION FOR LUNG CANCER BY COMBINING
GENETIC VARIANTS
Numerous groups have developed various risk models for lung
cancer (Bach et al., 2003; Cassidy et al., 2006; Spitz et al., 2007,
2009; Young et al., 2009c,d) but only two have used SNP-based
markers as part of their risk algorithm (Spitz et al., 2009; Young
et al., 2009b). The ﬁrst non-gene model by Bach used only age,
pack years, and asbestos exposure to determine risk of lung can-
cer (Bach et al., 2003). This has only limited predictive utility.
The non-gene risk models by Spitz et al. (2007) omitted age as
a risk variable while that of Field and colleagues (Cassidy et al.,
2006) omitted COPD. The best non-gene-based model to date
comes from a large prospective study based on the Prostate, Lung,
Colon, and Ovarian Cancer cohort (Tammemagi et al., 2011).
In this model, Tammemagi et al. (2011) include age, pack years
exposure, current smoking status, COPD, family history, dust
exposure, chest x-ray, and BMI. The predictive utility of these
models are often reported according to their receiver operator
curve (ROC) c statistic. While the ROCs of the Bach, Spitz,
Field, and Tammemagi models are reported to be 0.69, 0.59–0.65,
0.70, and 0.78–0.84, respectively, comparison of these models
is difﬁcult as performance of the models is highly dependent
on the populations in which they have been developed (smok-
ers and non-smokers, smokers only, or heavy smokers only;
Tammemagi et al., 2011). Similarly, the contribution of the com-
ponent risk factors, including genetic markers, is dependent on
the populations studied and the other variables in the model.
What is clearly shown by Tammemagi, is that combining these
variables achieves the greatest predictability and highlights how
important age, smoking history and COPD are in the model
(Tammemagi et al., 2011). In all models, age is one of the most
important variables and probably reﬂects important biological
effects from either the cumulative effects of smoking (or other
aero-pollutants) and/or the failure of the immune system to cope
with this exposure from about aged 40 years when the risk of
lung cancer increases in smokers above that of non-smokers or
after 60 years old when this risk increases exponentially (Woloshin
et al., 2008). While the Spitz model lacks age (Spitz et al., 2007)
and the Field model lacks COPD (Cassidy et al., 2006), none of
these models have incorporated genetics factors (other than family
history).
We have reported that genetic factors (SNP variants) signiﬁ-
cantly add to our lung cancer model (Young et al., 2009b,c). This
is important as it deﬁnes risk in people who are often too young
to have a positive family history or who have not yet been diag-
nosed with COPD. As will be discussed in the next section, this
group is important because they are at high risk of getting lung
cancer but may miss screening eligibility due to age restrictions
(Young and Hopkins, 2012a). Our model includes genes identi-
ﬁed by genome-wide studies to be implicated in lung cancer and
COPD (Figure 2; Young et al., 2011d). This is analogous to includ-
ing obesity genes in a risk model for diabetes (e.g., FTO – fat-free
mass gene) or cholesterol genes in a risk model for heart attack. In
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FIGURE 2 | Multivariate risk model to identify current and former smokers at greatest risk of lung cancer for targeted, cost-effective CT screening.
a ROC analysis of our gene-based risk model, the c statistic ranges
from 0.72 to 0.79 with the genetic risk score (from the combined
SNPpanel) contributing approximately 50%of the total predictive
utility, three- to fourfold greater than from family history alone
(Young et al., 2009b,c, 2011d). Not only does the genetic risk score
contribute to the overall score independently of the other vari-
ables, for younger smokers, the risk was entirely derived from their
SNP genotypes. In contrast to other risk models, our model was
developed by comparing heavy smokers withwidely disparate out-
comes (susceptible vs resistant). Using these cohorts of smokers,
we have been the ﬁrst to show that genes conferring susceptibil-
ity to lung cancer involved genes also conferring susceptibility to
COPD and vice-versa (Young et al., 2008, 2010b, 2011c,d). While
this might appear intuitive, of greater importance is that we found
some genes that confer a protective effect on COPD also confer
a protective effect for lung cancer (Young et al., 2010b, 2011c,d).
The contribution of these “protective” genes is very important
in our risk model as they help to distinguish smokers at least
genetic risk and most genetic risk (Young et al., 2009b,c), rather
than just those at the greater risk-based solely only susceptibility
SNPs (Spitz et al., 2009). What is important in these risk models
is that the combination of these variables is superior to the use of
only a few variables (e.g., age and smoking) and that genetic factors
must be used in combination with the relevant clinical variables to
have any useful predictive utility (Young et al., 2009b,c). Of note,
we have used susceptible and protective genotypes (rather than
alleles) in our risk score, better reﬂecting the effects conferred
by “smoking-sensitive” genes like the α1-anti-trypsin gene
(Young et al., 2012a).
An important limitation of many of the risk models described
above is that they have been developed in populations including
non-smokers or light smokers (Bach et al., 2003; Cassidy et al.,
2006; Tammemagi et al., 2011). When these people are included
in model development, factors such as smoking history become
more important than they would be if only heavy older smokers
were involved in model development (Tammemagi et al., 2011).
This might dilute out the effect of having COPD or genetic
effects (like family history or SNP variants) where smoking expo-
sure dose is critical to gene penetrance (Young and Hopkins,
2011d). The risk of lung cancer in these groups is too low to
be included in early diagnosis strategies like CT screening (dis-
cussed further below). Lung cancer risk models developed in these
wider populations, including low-risk people, might not perform
as well in identifying high risk of lung cancer in heavy smok-
ers where CT screening is recommended. Validation in the CT
screening studies will be needed to conﬁrm their utility in this
setting.
CLINICAL APPLICATION OF A LUNG CANCER RISK MODEL
IN CT SCREENING AND SMOKING CESSATION
Given lung cancer now accounts for between 20 and 30% of all
lung cancer deaths yet was rare before 1900 (Young et al., 2012a),
it is clear smoking is central to the development of lung can-
cer. However, genetic make-up is also important in determining
which smokers are highly susceptible or resistant to COPD and
lung cancer. The genetic factors underlying this predisposition
are now better understood thanks to the GWA studies that have
identiﬁed several genetic loci underlying COPD or lung cancer
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(Amos et al., 2008; Hung et al., 2008; Thorgeirsson et al., 2008;
Broderick et al., 2009; Castaldi et al., 2009; Pillai et al., 2009; Wilk
et al., 2009). The good news is both diseases can be all but pre-
vented if smokers quit before age 40 years old (Peto et al., 2000;
Anthonisen et al., 2005). Similarly, the progression of impaired
lung function to COPD and/or lung cancer (Peto et al., 2000;
Anthonisen et al., 2005) can be largely delayed if smokers with this
predisposition quit before too much lung damage is done. This
means that gene-based risk testing can identify high risk smok-
ers early in their lives, at a time when quitting might prevent the
development of these diseases. If our observations are correct, that
the pathogenic processes underlying COPD also predispose some
smokers to developing lung cancer, then prevention of the former
might also prevent development of the latter. In this regard novel
chemo-preventive approaches are also possible (Walser et al., 2008;
Young et al., 2009a).
In regards to smoking cessation, a recent review concluded
that while genetic tests can increase motivation to quit, there
is no conclusive evidence that gene-based risk testing (mostly
for lung cancer susceptibility), helps smokers quit (Smerec-
nik et al., 2012). However, this conclusion was based on single
marker tests where smokers were assigned as positive or negative
and the risk conferred by the test was small. In one under-
powered study, those smokers undergoing genetic testing had
increased quit rates at both 6 and 12 months (McBride et al.,
2002). Sadly data is limited in this regard. We have devel-
oped a multivariate gene-based risk test for lung cancer risk
that appears to increase smokers uptake of nicotine replacement
treatment and improves quit rate (Hopkins et al., 2011, 2012).
This observation is the subject of a follow-up study. The impor-
tant distinction with our test compared to the old single marker
tests (Smerecnik et al., 2012) is that no smokers are “negative,”
instead all smokers are at some degree of risk of lung cancer
and only non-smokers are at low risk. This is important as
smokers understand their risk of a smoking-related disease is
partly genetically determined and not “negative.” We suggest that
such a beneﬁcial effect might occur because gene-based testing
helps increase motivational tension and undermine unrealistic
optimism (Weinstein et al., 2005; Young et al., 2010a) in many
smokers.
The recent publication of the National Lung Screening Trial
(NLST) has conﬁrmed that annual lung CT screening of high risk
smokers for lung cancer reduces lung cancer mortality by 20%
(National Lung Screening Trial Research Team, 2011). However,
the eligibility criteria for that studywas based on age andpack years
only and effectively excludes over 50% of lung cancer cases due to
ineligibility for screening (Young andHopkins, 2012a). Recent rec-
ommendations have suggested that the age and pack years criteria
for CT screening be widened and that a multivariate approach be
used to identify the smokers at greatest risk (Bach et al., 2012; Jak-
litsch et al., 2012; Young and Hopkins, 2012b). We believe this is
the best way to correctly stratify smokers by risk level and iden-
tify those for whom CT screening is most appropriate. From a
cost-effective viewpoint, maximizing the detection rate of lung
cancer might help make screening more cost-effective (Figure 2;
Young et al., 2012b). We are currently undertaking a study where
our gene-based risk test for lung cancer is being assessed in NLST
participants to explore the utility of the test in improving the sen-
sitivity of current screening criteria and increasing lung cancer
detection rates.
SUMMARY
With recent advances in genetic epidemiology, there are a number
of genetic loci recently identiﬁed that underlie COPD and lung
cancer. We have identiﬁed that many of these genes are overlap-
ping and can be used in a lung cancer risk model in conjunction
with clinical variables. More importantly, this gene-based risk
model appears to be effective in engaging smokers in risk miti-
gating activities (Young and Hopkins, 2012c), a critical utility that
non-gene-based risk tools have yet to demonstrate. While further
studies are needed to conﬁrm these recent ﬁndings, it appears that
we are on the verge of being able to use gene-based risk mod-
els for assessing lung cancer susceptibility and engage smokers in
evidence-based risk mitigating activities.
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